Equity Profile

TARS

Tarsus Pharmaceuticals, Inc.

Health CarePharmaceuticals$2.6B

May6Wed

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Tarsus Pharmaceuticals Beats on EPS, Stock Down 0.43%

Metric	Actual	Expected	Surprise
EPS	$-0.16	$-0.21	+64.91%
Revenue	—	$153M	—

management commentary, guidance changes, and full analysis available with Pro.

Tarsus Pharmaceuticals Beats on EPS, Stock Down 0.43%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.16	$-0.21	+64.91%
Revenue	—	$153M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Tarsus Pharmaceuticals reported a narrower loss than expected, which is a positive sign for investors. However, the stock reacted negatively, declining by 0.43%. The lack of revenue reporting and guidance may have contributed to the stock's downward movement.

Company Snapshot

Tarsus Pharmaceuticals, Inc. (TARS) operates in the health care sector, focusing on developing innovative pharmaceutical solutions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Tarsus is managing its costs and revenue.

$-0.21

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$153M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Tarsus Pharmaceuticals, Inc. (TARS) operates in the health care sector, focusing on developing innovative pharmaceutical solutions. With a market cap of $3 billion, the company aims to address unmet medical needs, particularly in eye care, which is a growing area of interest in the pharmaceutical industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q4-2025, Tarsus reported an EPS of $-0.20, slightly missing expectations but showing a positive surprise compared to previous quarters. The stock reacted positively, gaining 4.47% the next day.

Management Promises & Guidance

Management indicated a focus on expanding product offerings.
They committed to improving operational efficiencies.
Plans to enhance marketing strategies for existing products were discussed.

Expectations

Wall Street Expectations

Analysts expect Tarsus to report a loss per share of $-0.21 and revenue of $153 million this quarter. The market is watching closely for any signs of growth or improvement in profitability.

Bull Case

If Tarsus exceeds revenue expectations and shows signs of narrowing losses, it could indicate strong demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses on both EPS and revenue, it may raise concerns about its growth trajectory and market competitiveness, potentially leading to a negative stock response.

Key Metrics to Watch

EPS

$-0.21

Earnings per share is a key indicator of profitability and will show how well Tarsus is managing its costs and revenue.

Revenue

$153M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Tarsus achieve revenue of at least $153 million this quarter?

Meeting or exceeding this revenue target would signal strong market demand and could boost investor confidence.

Can Tarsus narrow its EPS loss to $-0.21 or better?

A smaller loss than expected would indicate improved operational efficiency and could positively influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Tarsus's potential for revenue growth driven by recent product launches and market expansion efforts.

Supporting Evidence

The company's recent marketing strategies could lead to higher sales than anticipated.

Historical patterns show Tarsus has a strong track record of beating EPS estimates, suggesting a potential upside.

Options pricing indicates a significant move, which may reflect investor expectations of better-than-expected results.

Key Risk

If Tarsus's revenue exceeds $153 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to execute its growth strategy and manage costs effectively.

Bull Confirmed If

Revenue exceeding $153 million with an EPS loss of $-0.21 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.21 and revenue below $146 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.0%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±17.0% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

41.1%

Calls (900)P/C Ratio: 2.17Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations, history suggests a potential stock increase of around 2.83%, confirming positive market sentiment.

In-Line / Cautious

An in-line report could lead to a muted reaction, as investors may await further clarity on future growth prospects.

Miss

If Tarsus misses on both EPS and revenue, history suggests a potential decline of around 3.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product sales and market demand.
2Any commentary on cost management and operational efficiencies.
3Insights into future product pipeline and development timelines.
4Management's outlook on market conditions and competitive landscape.
5Details on marketing strategies and their effectiveness.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Tarsus Pharmaceuticals, Inc. (TARS) operates in the health care sector, focusing on developing innovative pharmaceutical solutions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well Tarsus is managing its costs and revenue.

$-0.21

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$153M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+14.49%

Avg Stock Reaction

-0.37%

Last Quarter Recap

In Q4-2025, Tarsus reported an EPS of $-0.20, slightly missing expectations but showing a positive surprise compared to previous quarters. The stock reacted positively, gaining 4.47% the next day.

Management Promises & Guidance

Management indicated a focus on expanding product offerings.
They committed to improving operational efficiencies.
Plans to enhance marketing strategies for existing products were discussed.

Expectations

Wall Street Expectations

Analysts expect Tarsus to report a loss per share of $-0.21 and revenue of $153 million this quarter. The market is watching closely for any signs of growth or improvement in profitability.

Bull Case

If Tarsus exceeds revenue expectations and shows signs of narrowing losses, it could indicate strong demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company misses on both EPS and revenue, it may raise concerns about its growth trajectory and market competitiveness, potentially leading to a negative stock response.

Key Metrics to Watch

EPS

$-0.21

Earnings per share is a key indicator of profitability and will show how well Tarsus is managing its costs and revenue.

Revenue

$153M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Tarsus achieve revenue of at least $153 million this quarter?

Meeting or exceeding this revenue target would signal strong market demand and could boost investor confidence.

Can Tarsus narrow its EPS loss to $-0.21 or better?

A smaller loss than expected would indicate improved operational efficiency and could positively influence stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Tarsus's potential for revenue growth driven by recent product launches and market expansion efforts.

Supporting Evidence

The company's recent marketing strategies could lead to higher sales than anticipated.

Historical patterns show Tarsus has a strong track record of beating EPS estimates, suggesting a potential upside.

Options pricing indicates a significant move, which may reflect investor expectations of better-than-expected results.

Key Risk

If Tarsus's revenue exceeds $153 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will reflect the company's ability to execute its growth strategy and manage costs effectively.

Bull Confirmed If

Revenue exceeding $153 million with an EPS loss of $-0.21 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than $-0.21 and revenue below $146 million would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.0%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±17.0% while TARS has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.1%

30d HV

41.1%

Calls (900)P/C Ratio: 2.17Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tarsus beats expectations, history suggests a potential stock increase of around 2.83%, confirming positive market sentiment.

In-Line / Cautious

An in-line report could lead to a muted reaction, as investors may await further clarity on future growth prospects.

Miss

If Tarsus misses on both EPS and revenue, history suggests a potential decline of around 3.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on product sales and market demand.
2Any commentary on cost management and operational efficiencies.
3Insights into future product pipeline and development timelines.
4Management's outlook on market conditions and competitive landscape.
5Details on marketing strategies and their effectiveness.